Perhaps, then, "CD30 Cell Depletion Therapy" might be more descriptively accurate......with the serum level of soluble CD30 being the related possible bio-marker of effect.
Of course, SGEN's ADC theoretically offers a much simpler " right off the shelf" therapy addressing of the basic pathophysiology as compared to a CAR T cell approach.
The following statement is absolute TOTAL speculation........... but, the addressable total population of such "potential" therapies in auto-immune and inflammatory disorders is logarithmic relative to HD alone.
Disclosure and warning: Ricardo has lost it. The above could be reality or fantasy......for Ricardo that line between the two is very thin indeed. Do not, repeat , do not base any investment decisions on the above ramblings of this individual.
Ricardo would like to add, at this time, a term to the medical therapeutic lexicon. It is, "CD30 Depletion Therapy".
It references the treatment of autoimmune and inflammatory disease states with agents that deplete CD30+ lymphocytes.
My question is: Has Ricardo gone totally bonkers? Is there hope for him......and, importantly, do you feel that this new term will ever find its way, in the future, into the established language of therapeutic medicine?
Best of luck to all !
Disclosure: Ricardo has a humongous long term position in the shares of SGEN. His opinions are, therefore, to be considered as totally biased. Listen to him only at your own peril. OK, you get the picture.
Yes, they do seem to be excited about this at UCLA.
See also the videos at:
I have a long term position in nwbo. Still consider it quite risky and speculative, but the confidence in the results being reportedly witnessed by physicians at a leading medical center in encouraging.
AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
Do you know for certain that this video is about nwbo treatment or another form of similar therapy?
I have been investing in pharma and bio for about 35 years. After yesterday's conference call, I just can't help thinking that this company has a few ( or more ) potentially explosive opportunities over the next few years. Not that any of them will be assuredly realized, with failures being a norm for the industry, but there is such lingering excitement.
I am talking about, for example, moving Adcetris towards earlier lines of treatment, SGN-33A for AML ( actually, there might be an even wider application in forms of myelodysplasia ), LIV-1 ADC in breast CA. Couple this with a solid royalty position and many milestones / partnerships, a good balance sheet and a reluctance of management to take on debt or issue an overwhelming number of new shares.........and the next three years "might" be quite amazing. Off course, we have to temper that with the reality that nothing usually ever goes smoothly or perfectly as planned with these sorts of ventures. Nonetheless, what I am simply saying is that the excitement ( at least for me ) is there.
Let's see what the next three years brings for anyone patient enough to hold this stock over this period of time.
Good luck to all!
CAUTION: Bias Disclosure: Ricardo owns a huge position in SGEN. Purchased mostly at relatively low prices years ago ( most lots at $4-8 ). He has sold off previously about 25% of his holdings to lock in a profit, but remains committed with the rest as a long term hold. Because of his large stake, his judgement may be quite distorted and he may be delusional so CAVEAT EMPTOR and do your own due diligence and research before investing.
Google: Brentuximab Vedotin Leah Lawrence
Interesting quote in the report:
“Once this is published, in this particular patient population … I do believe that it will become standard treatment,” Moskowitz during his oral abstract presentation.
Good luck to all !
atpl1959 : That's an interest thought.........because............
In patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse........there are data that suggest Adcetris ITSELF may be a reasonable retreatment option:
"At the 2012 ASCO Annual Meeting, retreatment data from the phase II trial were reported from 23 patients, including one patient who was treated twice. Patients had received a median of four prior systemic therapies, including ADCETRIS. Of 23 evaluable patients, 70 percent (16 of 23) achieved an objective response after retreatment with ADCETRIS, including nine complete remissions and seven partial remissions. Median duration of retreatment objective response was 8.8 months. Among retreated HL patients, nine of 16 (56 percent) achieved an objective response. Among retreated sALCL patients, seven of eight (88 percent) achieved an objective response. The most common adverse events were peripheral neuropathy (46 percent), nausea (42 percent), fatigue (38 percent), diarrhea (33 percent) and fever (29 percent). "
Yes, quite IMPRESSIVE data released today. I am not so sure the market is truly "worried".......Wall Street, day to day, is a fickle thing subject to manipulation. Hard to gauge just what is at work here. Good luck to all. Ricardo
-Long-Term Data from Phase 1 Trial of ADCETRIS Combined with AVD in Frontline Hodgkin Lymphoma Demonstrate 100 Percent Three-Year Overall Survival Rate and 92 Percent Three-Year Failure-Free Survival Rate; Data Provide Continued Strong Support for ECHELON-1 Trial-
-ADCETRIS in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma as Second-line Therapy Shows Objective Response Rate of 96 Percent and Complete Remission Rate of 83 Percent-
-Interim Data from ADCETRIS Phase 2 Clinical Trial in Previously Untreated Hodgkin Lymphoma Patients Age 60 or Older Demonstrate 93 Percent Objective Response Rate-
-Data from Multiple Trials Support Goal to Establish ADCETRIS as Foundation of Therapy in Frontline and Salvage Hodgkin Lymphoma and Other CD30-Positive Malignancies-
HAMPTON, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that it has initiated an open-label Phase 2 study of glembatumumab vedotin (CDX-011) in patients with unresectable Stage III or IV melanoma. Glembatumumab vedotin is a fully-human monoclonal antibody-drug conjugate (ADC) that targets glycoprotein NMB (gpNMB), a protein overexpressed by multiple tumor types, including metastatic melanoma where approximately 85% of patients overexpress the marker. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome. The study is expected to include up to 10 sites in the United States and will enroll approximately 60 patients. Glembatumumab vedotin was previously evaluated in a Phase 1/2 study in patients with unresectable stage III or stage IV melanoma, a Phase 1/2 study in advanced breast cancer, a Phase 2 study in advanced breast cancer (the EMERGE study) and is currently being evaluated in patients with metastatic triple negative breast cancers that overexpress gpNMB in the METRIC Study.